Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy

Journal of Clinical Investigation

Volumn 127, Issue 1, 2017, Pages 106-116

  Cunningham, Trevor J ^a,b   Tabacchi, Mary ^b   Eliane, Jean Pierre ^a   Tuchayi, Sara Moradi ^a   Manivasagam, Sindhu ^b   Mirzaalian, Hengameh ^c   Turkoz, Ahu ^d   Kopan, Raphael ^d   Schaffer, Andras ^e   Saavedra, Arturo P ^a   Wallendorf, Michael ^b   Cornelius, Lynn A ^b   Demehri, Shadmehr ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e Department of Pathology and Immunology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; FLUOROURACIL; HLA ANTIGEN CLASS 2; NATURAL KILLER CELL RECEPTOR NKG2D; PETROLATUM; THYMIC STROMAL LYMPHOPOIETIN; ANTINEOPLASTIC AGENT; CALCITRIOL; CYTOKINE;

ACTINIC KERATOSIS; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CELLULAR STRESS SIGNAL; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ERYTHEMA; FACE; FACE ERYTHEMA; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; KERATINOCYTE; LOCAL SKIN REACTION; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; OINTMENT; PIGMENT DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; PUSTULE; RANDOMIZED CONTROLLED TRIAL; SCALP; SCAR FORMATION; SKIN BURNING SENSATION; SKIN CANCER; SKIN CARCINOGENESIS; SKIN CRUSTING; SKIN INFECTION; SKIN INJURY; SKIN MANIFESTATION; SKIN OOZING; SKIN PAIN; SKIN REDNESS; SKIN SCALING; SKIN VESICULATION; SYSTEMIC DISEASE; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; UPPER LIMB; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KERATOSIS, ACTINIC; MIDDLE AGED; PATHOLOGY; PRECANCEROUS CONDITIONS; SKIN NEOPLASMS; TOPICAL DRUG ADMINISTRATION; TRANSGENIC MOUSE; VERY ELDERLY;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITRIOL; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FLUOROURACIL; HUMANS; IMMUNITY, CELLULAR; KERATOSIS, ACTINIC; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; PRECANCEROUS CONDITIONS; SKIN NEOPLASMS;

EID: 85008414660     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI89820     Document Type: Article

References (35)

1. Demehri S, Turkoz A, Manivasagam S, Yockey LJ, Turkoz M, Kopan R. Elevated epidermal thymic stromal lymphopoietin levels establish an antitumor environment in the skin. Cancer Cell. 2012;22(4):494-505.
2. Di Piazza M, Nowell CS, Koch U, Durham AD, Radtke F. Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting. Cancer Cell. 2012;22(4):479-493.
3. Cipolat S, Hoste E, Natsuga K, Quist SR, Watt FM. Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility. Elife. 2014;3:e01888.
4. Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol. 2010;11(4):289-293.
5. Wang H, Diepgen TL. Atopic dermatitis and cancer risk. Br J Dermatol. 2006;154(2):205-210.
6. Wang H, Diepgen TL. Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy. 2005;60(9):1098-1111.
7. Van Hemelrijck M, et al. Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes Control. 2010;21(10):1657-1667.
8. Hwang CY, et al. Cancer risk in patients with allergic rhinitis, asthma and atopic dermatitis: a nationwide cohort study in Taiwan. Int J Cancer. 2012;130(5):1160-1167.
9. Li M, Hener P, Zhang Z, Kato S, Metzger D, Chambon P. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci U S A. 2006;103(31):11736-11741.
10. Li M, Hener P, Zhang Z, Ganti KP, Metzger D, Chambon P. Induction of thymic stromal lymphopoietin expression in keratinocytes is necessary for generating an atopic dermatitis upon application of the active vitamin D3 analogue MC903 on mouse skin. J Invest Dermatol. 2009;129(2):498-502.
11. Sato-Deguchi E, Imafuku S, Chou B, Ishii K, Hiromatsu K, Nakayama J. Topical vitamin D(3) analogues induce thymic stromal lymphopoietin and cathelicidin in psoriatic skin lesions. Br J Dermatol. 2012;167(1):77-84.
12. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):4-7.
13. Fenske NA, Spencer J, Adam F. Actinic keratoses: past, present and future. J Drugs Dermatol. 2010;9(5 Suppl ODAC Conf Pt 1):s45-s49.
14. Stockfleth E, et al. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol. 2008;18(6):651-659.
15. Stockfleth E, et al. Physician perceptions and experience of current treatment in actinic keratosis. J Eur Acad Dermatol Venereol. 2015;29(2):298-306.
16. Warino L, Tusa M, Camacho F, Teuschler H, Fleischer AB, Feldman SR. Frequency and cost of actinic keratosis treatment. Dermatol Surg. 2006;32(8):1045-1049.
17. Zhang Z, et al. Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc Natl Acad Sci U S A. 2009;106(5):1536-1541.
18. Abel EL, Angel JM, Kiguchi K, DiGiovanni J. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc. 2009;4(9):1350-1362.
19. Ito K, Koga M, Shibayama Y, Tatematsu S, Nakayama J, Imafuku S. Proactive treatment with calcipotriol reduces recurrence of plaque psoriasis. J Dermatol. 2016;43(4):402-405.
20. Seckin D, Cerman AA, Yildiz A, Ergun T. Can topical calcipotriol be a treatment alternative in actinic keratoses? A preliminary report. J Drugs Dermatol. 2009;8(5):451-454.
21. Kaur RR, Alikhan A, Maibach HI. Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment. J Dermatolog Treat. 2010;21(5):267-271.
22. Khallouf H, et al. 5-Fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class I. J Immunother. 2012;35(3):245-253.
23. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72.
24. Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest. 2012;122(2):464-472.
25. Demehri S, et al. Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis. J Clin Invest. 2016;126(4):1458-1470.
26. Clark RA. Resident memory T cells in human health and disease. Sci Transl Med. 2015;7(269):269.
27. Martincorena I, et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015;348(6237):880-886.
28. Lian CG, et al. Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury. Mod Pathol. 2014;27(6):788-799.
29. Black AP, et al. Human keratinocyte induction of rapid effector function in antigen-specific memory CD4+ and CD8+ T cells. Eur J Immunol. 2007;37(6):1485-1493.
30. Strid J, Sobolev O, Zafirova B, Polic B, Hayday A. The intraepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy. Science. 2011;334(6060):1293-1297.
31. Pomerantz H, et al. Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. JAMA Dermatol. 2015;151(9):952-960.
32. Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010;62(4):573-581.
33. Drobits B, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest. 2012;122(2):575-585.
34. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146(1):94-100.
35. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010-1019.